一周IPO动态，覆盖港股、美股、A股。 本文为IPO早知道原创 作者｜C叔 微信公众号｜ipozaozhidao 映恩生物 港股｜挂牌上市 据IPO早知道消息，Duality Biotherapeutics, Inc.（以下简称"映恩生物"）于2025年4月15日正式 以"9606"为股票代码在港交所主板挂牌上市。 映恩生物在本次IPO中发行17,332,300股股份，相较早前的发行计划有所提升。其中，香港公开发 售获115.14倍认购，国际发售获13.52倍认购。 同时，映恩生物在本次IPO发行中总计引入十余家基石投资者，累计认购规模6500万美元（5.05亿 港元）——BioNTech SE(Nasdaq: BNTX)认购500万美元、礼来认购500万美元、清池资本（Lake Bleu Prime）认购500万美元、TruMed Investment认购1000万美元、富国基金认购1000万美元、 易方达基金认购800万美元、汇添富基金认购600万美元、磐京基金认购500万美元、MY.Alpha Management认购500万美元、Exome Asset Management认购400万美元、苏州苏创认 ...

Core Viewpoint - The company, Innovent Biologics, has successfully transitioned from a "domestic ADC dark horse" to a "star player in the Hong Kong 18A sector," achieving the largest fundraising scale in the biotech sector since 2022 and leading the IPO first-day gain rankings for 2025 in Hong Kong [1][2]. Fundraising and IPO Performance - Innovent Biologics' IPO price was set at HKD 94.60 per share, raising approximately USD 211 million (around RMB 1.54 billion), with the total amount potentially increasing to USD 243 million upon full exercise of the greenshoe option, marking the largest IPO in the Hong Kong 18A sector in nearly four years [1]. - On its first trading day, the stock surged by 116.7%, reaching a peak price of HKD 222, a significant increase of 134.67% from the IPO price, with total trading volume exceeding HKD 2 billion, reflecting strong market confidence in the company [1]. Investment Interest and Strategic Partnerships - Prior to the IPO, Innovent Biologics attracted significant interest from investors, securing commitments from 15 cornerstone investors totaling USD 65 million (approximately HKD 505 million), including prominent firms like BioNTech SE and Eli Lilly, as well as top domestic funds [2]. - The company is positioned as a key player in the ADC field, focusing on developing innovative ADC drugs for cancer and autoimmune diseases, which is crucial for long-term investment considerations [2]. R&D Capabilities and Product Pipeline - The core value of ADC innovation companies lies in platform and drug value, and Innovent Biologics boasts a strong technical team with over 20 years of experience, having developed four next-generation ADC technology platforms and a differentiated pipeline of 13 self-developed ADC candidates [3]. - The company has received recognition from international authorities for its core technologies and pipeline, with three products, including DB-1303 and DB-1311, having received FDA fast track designations, and DB-1303 also recognized as a breakthrough therapy [3]. Market Position and Future Outlook - Innovent Biologics has established itself as a leader in ADC drug innovation, securing over USD 6 billion in total value from multiple business development transactions with top global pharmaceutical companies since 2023 [4]. - The company is transitioning its growing innovation potential into commercial momentum, with a clear path to revenue generation and cash flow from clinical development, setting the stage for further valuation growth as core products reach the market [4].

一周IPO动态，覆盖港股、美股、A股。 本文为IPO早知道原创 作者｜C叔 微信公众号｜ipozaozhidao 映 恩生 物 港股｜上市在即 据IPO早知道消息，Duality Biotherapeutics, Inc.（以下简称"映恩生物"）计划于2025年4月15日 正式以"9606"为股票代码在港交所主板挂牌上市。 映恩生物计划在本次IPO中发行15,071,600股股份。其中，香港公开发售1,507,200股股份，国际发 售13,564,400股股份。 值得注意的是，映恩生物在本次IPO发行中总计引入十余家基石投资者，累计认购规模6500万美元 （5.05亿港元）——BioNTech SE(Nasdaq: BNTX)认购500万美元、礼来认购500万美元、清池资 本（Lake Bleu Prime）认购500万美元、TruMed Investment认购1000万美元、富国基金认购 1000万美元、易方达基金认购800万美元、汇添富基金认购600万美元、磐京基金认购500万美元、 MY.Alpha Management认购500万美元、Exome Asset Management认购400万美元、苏 ...